Harrow Q1 revenue $44.2M, net loss $27.6M; VEVYE market share reaches 14%

HARROW, INC.

2026-Q1 EPS reported -$0.74 vs consensus -$0.41 ▼ miss (-80.7%)

Revenue of $44.2M, down 8% YoY, including ~$8M non-recurring gross-to-net adjustment related to new VEVYE commercial coverage.
Net loss of $27.6M ($0.74 diluted EPS) vs. loss of $17.8M ($0.50) in Q1 2025; Adjusted EBITDA -$12.7M.
VEVYE delivered record quarterly prescriptions: NRx +25% QoQ, TRx +11% QoQ; surpassed XIIDRA on monthly TRx with ~14% market share.
IHEEZO unit demand +18% YoY to 45,509 units (82% from retina); TRIESENCE unit demand +136% YoY for 6th consecutive growth quarter.
Q2 2026 revenue guidance $71M-$81M; full-year 2026 revenue reaffirmed $350M-$365M, Adjusted EBITDA $80M-$100M.

item 2.02item 7.01item 9.01

Source: SEC EDGAR

accession 0001493152-26-022227

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.